人前列腺癌多药耐药细胞系的建立  

Establishment of multidrug resistance cell line from human prostatic cancinoma

作　　者：潘玉琢[1] 赵燕颖[1] 赵雪俭[1] 李扬[1] 

机构地区：[1]吉林大学基础医学院病理生理学教研室吉林大学前列腺疾病防治研究中心,吉林长春130021

出　　处：《吉林大学学报（医学版）》2007年第4期651-654,F0002,共5页Journal of Jilin University：Medicine Edition

基　　金：国家科技部国际重点科技合作基金资助课题(2004DFB02000)

摘　　要：目的:建立人前列腺癌多药耐药细胞系。方法:以顺铂为诱导药物,人前列腺癌细胞PC3M为诱导对象,采用大剂量冲击与逐步增加剂量相结合的方法,诱导建立人前列腺癌多药耐药细胞系PC3M/CDDP;MTT法检测药物敏感性,免疫细胞化学法检测P-糖蛋白(P-gP)、多药耐药相关蛋白(MRP)的表达。结果:经顺铂诱导建立的人前列腺癌细胞系PC3M/CDDP对顺铂、丝裂霉素、阿霉素、5-氟尿嘧啶、长春新碱等药物的50%抑制浓度(IC50)分别为(0.603±0.102)、(0.201±0.056)、(0.267±0.067)、(1.676±0.321)和(0.657±0.227)mg·L-1,与PC3M细胞系比较差异有显著性(P<0.05);免疫细胞化学染色结果显示,PC3M/CDDP细胞系MRP、P-gP表达强度明显大于PC3M细胞系(P<0.05);PC3M/CDDP细胞系的细胞倍增时间为40.5h,与PC3M细胞系(48.6h)比较差异无显著性(P>0.05)。结论:成功建立稳定的人前列腺癌PC3M/CDDP细胞系,该细胞系具有对多种抗癌药耐药及细胞增殖未受影响的特点,可应用于下游实验。Objective To establish a multidrug resistance cell line from human prostatic cancinoma PC3M cell line. Methods The human prostatic cancinoma cell line PC3M was exposed to cisplatin with high dose and the concentration of cisplatin was increased gradually and then multidrug resistance cell line （PC3M/ CDDP） was established. The relative resistance was tested with MTT assay. The expressions of P-glycoprotein （P-gP） and multidrug resistance-related protein （MRP） were observed with immunocytochemical method. Results The IC50 of cisplatin, mitomycin, doxorubicin, 5-fluorouracil, vincristine on PC3M/CDDP cell were （0. 603 ± 0. 102）, （0.201±0.056）, （0.267±0.067）, （1.676±0.321） and （0.657±0.227） mg·L^1, respectively, there was significant difference of IC50 between PC3M/CDDP cell and PC3M cell （P〈0. 05）. The MRP and P-gP expressions of PC3M/CDDP cell were higher than those of PC3M cells （P〈0.05）. The proliferation rate of PC3M/CDDP cell （40.5h） had no obvious difference when compared with that of PC3M cell （48.6 h） （P〉0.05）. Conclusion A multidrug resistance cell line （PC3M/CDDP） is established from human prostatic cancinoma PC3M cell line. The PC3M/CDDP cell was resistant to mulidrug, and no change on cell proliferation. It can be used to downstream experiment.

关 键 词：人前列腺癌细胞 多药耐药相关蛋白质类 P-糖蛋白 抗肿瘤药 

分 类 号：R737.25[医药卫生—肿瘤] Q813.11[医药卫生—临床医学]